N-Acetyl-L-Leucine clinical trials
N-Acetyl-L-Leucine is named as an intervention in 3 current clinical trials in our UK, USA, Germany, Switzerland, Italy, Austria, Spain, Netherlands, Czechia and Australia registers. 1 is recruiting patients now. All registered phases are Phase 3. The lead sponsor is IntraBio Inc. The most-studied condition is CACNA1A.
Where N-Acetyl-L-Leucine is approved
All regulators →Of the three regulators tracked here, the first to approve N-Acetyl-L-Leucine was the US, on 24 Sep 2024.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
N-Acetyl-L-Leucine patents and exclusivity
Expiry tracker →Protections still running for marketed products containing N-Acetyl-L-Leucine, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 4 listed patents; the last listed expires 19 Apr 2037 (US 11400067).
- Exclusivity ODE-498: Orphan drug exclusivity: treatment of neurological manifestations of niemann-pick disease type c (npc) in adults and pediatric patients wei…, until 24 Sep 2031.
- Exclusivity NCE: New chemical entity, until 24 Sep 2029.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on N-Acetyl-L-Leucine
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
Patient leaflets for N-Acetyl-L-Leucine
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of N-Acetyl-L-Leucine
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
NCT05163288 · Niemann-Pick Disease, Type C
|
Phase 3 | Recruiting | IntraBio Inc | UK, USA, Germany, Netherlands, Switzerland, Czechia, Australia |
|
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056 · Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
|
Phase 3 | Active, closed | IntraBio Inc | UK, USA, Germany, Spain, Switzerland |
|
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292 · CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2
|
Phase 3 | Active, closed | IntraBio Inc | UK, USA, Germany, Italy, Switzerland, Austria |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with N-Acetyl-L-Leucine
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| IntraBio Inc | 3 |
By country register
A trial with sites in more than one country appears in each of those registers.
Questions about N-Acetyl-L-Leucine trials
How many clinical trials are testing N-Acetyl-L-Leucine?
3 current trials in our UK, USA, Germany, Switzerland, Italy, Austria, Spain, Netherlands, Czechia and Australia registers name N-Acetyl-L-Leucine (also registered as IB1001) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are N-Acetyl-L-Leucine trials recruiting patients?
Yes. 1 of the 3 trials is recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany, 1 with sites in Switzerland, 1 with sites in Netherlands, 1 with sites in Czechia and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors N-Acetyl-L-Leucine clinical trials?
The lead sponsor is IntraBio Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how N-Acetyl-L-Leucine works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how N-Acetyl-L-Leucine works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists N-Acetyl-L-Leucine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.